17q12-21 - The pursuit of targeted therapy in breast cancer

Cancer Treatment Reviews

Volumn 36, Issue 3, 2010, Pages 224-229

  Glynn, R W ^a   Miller, N ^a   Kerin, M J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

GRB7; HER2 neu; HER2 neu amplicon; RARA; STARD3; TOP2A

Indexed keywords

CHROMOSOME PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; START DOMAIN CONTAINING 3 PROTEIN; TAMOXIFEN; TOPOISOMERASE 2ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESISTANCE; CHOLESTEROL TRANSPORT; CHROMOSOME 17; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENE DELETION; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; STEROIDOGENESIS;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE TARGETING; GRB7 ADAPTOR PROTEIN; HUMANS; MEMBRANE PROTEINS; RECEPTORS, RETINOIC ACID;

EID: 77951204423     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.12.007     Document Type: Review

References (58)

1. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
2. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
3. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin adjuvant (HERA) trial study team trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
5. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
6. Smith I., Proctor M., Gelber R.D., et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007, 369:29-36.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007;131:18.
8. Barberis M., Pellegrini C., Cannone M., Arizzi C., Coggi G., Bosari S. Quantitative PCR and HER2 testing in Breast Cancer-a technical and cost-effectiveness analysis. Am J Clin Pathol 2008, 129:563-570.
9. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast cancers. Nature 2000, 406:747-772.
10. Sorlie T., Tibshirani R., Parker J. Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
11. Arriola E., Marchio C., Tam D.S.P., et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008, 88:491-503.
12. Kauraniemi P., Barlund M., Monni O., Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001, 61:8235-8240.
13. Kauraniemi P., Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006, 13:39-49.
14. Tanner M., Hollmen M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase 2 alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278.
15. Hansel D.E., Ashfaq R., Rahman A., et al. A subset of pancreatic adenocarcinomas demonstrates co-amplification of topoisomerase 2-alpha and HER2/neu: use of immunolabeling and multicolour FISH for potential patient screening and treatment. Am J Clin Pathol 2005, 123:28-35.
16. Murphy A.J., Hughes C.A., Barrett C., et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res 2007, 67:2893-2898.
17. Simon R., Atefy R., Wagner U., et al. HER-2 and TOP2A co-amplification in urinary bladder cancer. Int J Cancer 2003, 107:764-772.
18. Coon J.S., Marcus E., Gupta-Burt S., et al. Amplification and overexpression of topoisomerase II{alpha} predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002, 8:1061-1067.
19. Arriola E., Rodriguez-Pinella S.M., Lambros M.B., et al. Topisomerase 2 alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007, 106:181-189.
20. Knoop A.S., Knudsen H., Balslev E., et al. Danish breast cancer cooperative group retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish breast cancer cooperative group. J Clin Oncol 2005, 23:7483-7490.
21. Tanner M., Isola J., Wiklund T., et al. Topoisomerase II{alpha} gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast group trial 9401. J Clin Oncol 2006, 24:2428-2436.
22. Keith W.N., Douglas F., Wishart G.C., et al. Co-amplification of erbB2, topoisomerase 2-alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase 1 on chromosome 20. Eur J Cancer 1993, 29A:1469-1475.
23. Jarvinen T.A., Tanner M., Bärlund M., Borg A., Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999, 26:42-150.
24. Hicks D.G., Yoder B.J., Pettay J., et al. The incidence of topoisomerase 2-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridisation study. Hum Pathol 2005, 36:348-356.
25. Withoff S., De Jong S., De Vries E.G., Mulder N.H. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Anticancer Res 1996, 16:1867-1880.
26. Jacobson K.K., Morrison L.E., Henderson B.T., et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosom Cancer 2004, 40:19-31.
27. Bofin A.M., Ytterhus B., Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003, 14:314-319.
28. Beser A.R., Tuzlali S., Guzey D., Dolek Guler S., Hacihanefioglu S., Dalay N. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 2007, 13:180-185.
29. Mueller R.E., Parkes R.K., Andrulis I., O'Malley F.P. Amplification of the TOP2A gene does not predicet high levels of Topisomerase 2 alpha protein in human breast tumour samples. Genes Chromosom Cancer 2004, 39:288-297.
30. Isaacs R.J., Harris A.L., Hickson I.D. Regulation of the human topoisomerase II alpha gene promoter in confluence-arrested cells. J Biol Chem 1996, 271:16741-16747.
31. Isaacs R.J., Davies S.L., Sandri M.I., Redwood C., Wells N.J., Hickson I.D. Physiological regulation of eukaryotic topoisomerase II. Review. Biochim Biophys Acta 1998, 1400:121-137.
32. Marchio C., Natrajan R., Shiu K.K., et al. The genomic profile of Her2-amplified breast cancers: the influence of ER status. J Pathol 2008, 216:399-407.
33. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Review. Anticancer Res 1996, 16:2415-2419.
34. Soprano D.R., Qin P., Soprano K.J. Retinoic acid receptors and cancers. Annu Rev Nutr 2004, 24:201-221.
35. Schug T.T., Berry D.C., Toshkov I.A., Cheng L., Nikitin A.Y., Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci 2008, 105:7546-7551.
36. Frankel S.R., Eardley A., Heller G., et al. All-trans retinoic acid for acute promyelocytic leukaemia: Results of the New York study. Ann Intern Med 1994, 120:278-286.
37. Afonja O., Juste D., Das S., Matsuhashi S., Samuels H.H. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen, and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004, 23:8135-8145.
38. Tari A.M., Lim S.J., Hung M.C., Esteva F.J., Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 2002, 21:5224-5232.
39. Moog-Lutz C., Tomasetto C., Régnier C.H., et al. MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. Int J Cancer 1997, 71:183-191.
40. Strauss J.F., Kishida T., Christenson L.K., Fujimoto T., Hiroi H. START domain proteins and the intracellular trafficking of cholesterol in steroidogenic cells. Mol Cell Endocrinol 2003, 202:59-65.
41. Alpy F., Boulay A., Moog-Lutz C., et al. Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp//KLF transcription factors. Oncogene 2003, 22:3770-3780.
42. Tomasetto C., Régnier C., Moog-Lutz C. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics 1995, 28:367-376.
43. Dressman M.A., Baras A., Malinowski R., et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003, 63:2194-2199.
44. Vinatzer U., Dampier B., Streubel B., et al. Expression of HER2 and the co-amplified genes GRB7 and MLN64 in human breast cancer: Quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 2005, 11:8348-8357.
45. Kao J., Pollack J.R. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of co-amplified genes. Genes Chromosomes Cancer. 2006, 45:761-769.
46. Alpy F., Stoeckel M., Dierich A., et al. The Steroidogenic Acute Regulatory Protein Homolog MLN64, a Late Endosomal Cholesterol-binding Protein. J Biol Chem 2001, 276:4261-4269.
47. Akiyama N., Sasaki H., Ishizuka T., et al. Isolation of a candidate gene, CAB1, for cholesterol transport to mitochondria from the c-ERBB-2 amplicon by a modified cDNA selection method. Cancer Res 1997, 57:3548-5353.
48. Flynn D.C. Adaptor proteins. Oncogene 2001, 20:6270-6272.
49. Han D.C., Shen T.L., Guan J.L. The GRB7 family proteins: structure, interactions with other signaling molecules and potential cellular functions. Oncogene 2001, 20:6315-6321.
50. Stein D., Wu J., Fugua S.A., et al. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 1994, 13:1331-1340.
51. Pero S.C., Oligino L., Daly R.J., et al. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of GRB7. J Biol Chem 2002, 277:11918-11926.
52. Shen T.L., Guan J.L. Differential regulation of cell migration and cell cycle progression by FAK complexes with Src, PI3K, GRB7 and GRB2 in focal contacts. FEBS Lett 2002, 499:176-181.
53. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
54. Tanaka S., Suigimachi K., Kawaguchi H., Saeki H., Ohno S., Wands J.R. GRB7 signal transduction protein mediates metastatic progression of esophageal carcinoma. J Cell Physiol 2000, 183:411-415.
55. Kishi T., Sasaki H., Akiyama N., et al. Molecular cloning of human GRB-7 co-amplified with CAB1 and c-ERBB-2 in primary gastric cancer. Biochem Biophys Res Commun 1997, 232:5-9.
56. Itoh S., Taketomi A., Tanaka S., et al. Role of growth factor receptor bound protein 7 in hepatocellular carcinoma. Mol Cancer Res 2007, 57:667-673.
57. Tanaka S., Nakamura N., Kawamura T., Teramoto K., Arii S. Novel molecular targeting peptide therapy for pancreatic cancer metastasis. Review. Nippon Rinsho 2006, Suppl. 1:283-287. Japanese.
58. van Agthoven T., Veldscholte J., Smid M., et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009, 114:23-30. Epub 2008 Mar 21.